Last update 21 Nov 2024

Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells(First Affiliated Hospital of Zhejiang University)

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms-
Target
CD19 x CD20
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), Immunologic cytotoxicity
+ [1]
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication-
Inactive Indication
Diffuse large B-cell lymphoma recurrent
Originator Organization
The First Affiliated Hospital,Zhejiang University School of Medicine
Active Organization-
Inactive Organization
The First Affiliated Hospital, Zhejiang University School of Medicine
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells(First Affiliated Hospital of Zhejiang University)
NCT04486872 / Unknown statusPhase 1IIT
A Single-arm, Open-label, Dose Escalation Study to Explore Safety, Efficacy and Pharmacokinetics of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
100 Clinical Results associated with Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells(First Affiliated Hospital of Zhejiang University)
Login to view more data
100 Translational Medicine associated with Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells(First Affiliated Hospital of Zhejiang University)
Login to view more data
100 Patents (Medical) associated with Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells(First Affiliated Hospital of Zhejiang University)
Login to view more data
100 Deals associated with Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells(First Affiliated Hospital of Zhejiang University)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse large B-cell lymphoma recurrentPhase 1
CN
The First Affiliated Hospital, Zhejiang University School of Medicine
25 Jul 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free